Incretin-based therapy: renal effects
Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic ki...
Enregistré dans:
Auteurs principaux: | Anton Ivanovich Korbut, Vadim Valerievich Klimontov |
---|---|
Format: | article |
Langue: | EN RU |
Publié: |
Endocrinology Research Centre
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/5c2fe686f9b64d1a9647f4b4cad14b69 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The associations of incretin hormone concentration with gestational diabetes mellitus
par: Tatiana V. Saprina, et autres
Publié: (2016) -
The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
par: Juris J. Meier
Publié: (2019) -
Incretins today: multiple effects and therapeutic potential
par: Oksana V. Tsygankova, et autres
Publié: (2019) -
New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
par: Ekaterina Alekseevna Shestakova
Publié: (2011) -
Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
par: Alexander Sergeevich Ametov, et autres
Publié: (2011)